Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
IDH2 mutation + NTRK1 fusion
Cancer:
Astrocytoma
Drug:
Vitrakvi (larotrectinib)
(
TrkB receptor inhibitor
,
TrkC kinase inhibitor
,
TrkA receptor inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...NTRK gene fusion tumors...Larotrectinib
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.